Dec 10, 2024 · 1. Treatment of patients with tyrosine kinase inhibitor (TKI)-naïve epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) with osimertinib and ramucirumab resulted in a significantly longer progression-free survival (PFS) compared with osimertinib alone. Evidence Rating Level: 1 (Excellent) Study Rundown: The current standard of care for patients with advanced EGFR ...

Nov 21, 2024 · 1. In this randomized controlled trial, adjuvant therapy with durvalumab led to improved overall and progression-free survival compared to placebo in patients with limited-stage small cell lung cancer (SCLC). 2. Durvalumab had a tolerable safety profile, with a comparable incidence of adverse effects to the placebo group. Evidence Rating Level: 1 (Excellent) Study Rundown: Small

Dec 23, 2024 · 1. Local progression-free survival at 3 years was 84.3% in the SBRT group vs 67.3% in the RFA group, with HR 0.45 (significant). 2. HR for progression-free survival (HR 0.76) and overall survival (HR 0.91) was nonsignificant. Evidence Rating Level: 1 (Excellent) Study Rundown: Radiofrequency ablation (RFA), an effective and routine treatment for both primary

Dec 17, 2024 · 1. The large language model, ChatGPT-4, answered 85.0% of examination-style multiple-choice questions on medical oncology correctly, a performance superior to all other large language models and comparable with medical oncology trainees. 2. Approximately 80% of incorrect answers were rated by clinicians as having a …

Nov 26, 2024 · 1. In this randomized controlled trial of patients with heart failure and mildly decreased or preserved ejection fraction, finerenone treatment was associated with lower rates of worsening heart failure events. 2. Finerenone treatment was not associated with an increase in serious adverse events. Evidence Rating Level: 1 (Excellent) Study Rundown: Finerenone, a nonsteroidal mineralocorticoid ...

Dec 10, 2024 · 1. In this randomized controlled trial, in older adults with non-ST-segment elevation myocardial infarction (NSTEMI), invasive treatment did not significantly reduce the composite risk of cardiovascular death or nonfatal MI compared to conservative treatment. 2. There were fewer occurrences of fatal or nonfatal MI in patients in the invasive-strategy group than in the conservative-strategy group.

Oct 9, 2024 · 1. In this randomized controlled trial of men aged 50 to 60, forgoing prostate biopsies in those with elevated PSA but negative MRI reduced the diagnosis of clinically insignificant cancer. 2. MRI-negative men who did not undergo prostate biopsy did not have higher rates of incurable cancer diagnoses in follow-up screenings. Evidence Rating Level: 1

Oct 3, 2024 · 1. In this randomized controlled trial, among patients with moderately to severely active ulcerative colitis, tulisokibart, a monoclonal antibody directed against TL1A, more effectively induced clinical remission compared with placebo. 2. Compared with placebo, the tulisokibart group consistently showed benefits in clinical response, endoscopic improvement, histologic improvement, symptomatic ...

Jan 7, 2025 · 1. In a cohort of adults with chronic obstructive pulmonary disease (COPD), receiving fluticasone-umeclidinium-vilanterol was not associated with improved clinical outcomes compared to receiving budesonide-glycopyrrolate-formoterol. Evidence Rating Level: 2 (Good) Treatment recommendations for chronic obstructive pulmonary disease (COPD) include triple inhaler combination therapy with an ...

Nov 18, 2024 · 1. The 2-year progression-free survival was 50.6% in the durvalumab group vs 63.7% in the cetuximab group with HR 1.33 (non-significant). 2. Regarding safety, grade 3-4 adverse events occurred in 61% for durvalumab and 79% for cetuximab. Evidence Rating Level: 1 (Excellent) Study Rundown: Concurrent radiotherapy with cisplatin is the standard treatment for locoregionally advanced